|
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RIC1 |
Gene summary for RIC1 |
| Gene information | Species | Human | Gene symbol | RIC1 | Gene ID | 57589 |
| Gene name | RIC1 homolog, RAB6A GEF complex partner 1 | |
| Gene Alias | CATIFA | |
| Cytomap | 9p24.1 | |
| Gene Type | protein-coding | GO ID | GO:0003330 | UniProtAcc | Q4ADV7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57589 | RIC1 | CCI_1 | Human | Cervix | CC | 4.55e-13 | 1.04e+00 | 0.528 |
| 57589 | RIC1 | CCI_2 | Human | Cervix | CC | 6.32e-16 | 1.63e+00 | 0.5249 |
| 57589 | RIC1 | CCI_3 | Human | Cervix | CC | 1.57e-07 | 5.96e-01 | 0.516 |
| 57589 | RIC1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.76e-09 | -4.06e-01 | 0.0155 |
| 57589 | RIC1 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.42e-04 | -2.98e-01 | -0.1464 |
| 57589 | RIC1 | HTA11_866_2000001011 | Human | Colorectum | AD | 6.01e-05 | -3.25e-01 | -0.1001 |
| 57589 | RIC1 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.87e-04 | -3.66e-01 | 0.096 |
| 57589 | RIC1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.77e-09 | -3.83e-01 | 0.0674 |
| 57589 | RIC1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.39e-05 | -3.12e-01 | 0.294 |
| 57589 | RIC1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.35e-03 | -2.64e-01 | 0.3859 |
| 57589 | RIC1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.52e-03 | -5.04e-01 | 0.2585 |
| 57589 | RIC1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.57e-13 | -4.42e-01 | 0.3005 |
| 57589 | RIC1 | A001-C-207 | Human | Colorectum | FAP | 9.67e-03 | -2.40e-01 | 0.1278 |
| 57589 | RIC1 | A015-C-203 | Human | Colorectum | FAP | 1.96e-19 | -3.79e-01 | -0.1294 |
| 57589 | RIC1 | A015-C-204 | Human | Colorectum | FAP | 3.22e-04 | -2.28e-01 | -0.0228 |
| 57589 | RIC1 | A014-C-040 | Human | Colorectum | FAP | 2.69e-03 | -4.05e-01 | -0.1184 |
| 57589 | RIC1 | A002-C-201 | Human | Colorectum | FAP | 1.37e-08 | -2.36e-01 | 0.0324 |
| 57589 | RIC1 | A002-C-203 | Human | Colorectum | FAP | 8.71e-03 | -1.58e-01 | 0.2786 |
| 57589 | RIC1 | A001-C-119 | Human | Colorectum | FAP | 4.83e-05 | -3.84e-01 | -0.1557 |
| 57589 | RIC1 | A001-C-108 | Human | Colorectum | FAP | 9.15e-16 | -3.60e-01 | -0.0272 |
| Page: 1 2 3 4 5 6 |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD | ![]() |
| Colorectum | SER | ![]() |
| Colorectum | MSS | ![]() |
| Colorectum | MSI-H | ![]() |
| Colorectum | FAP | ![]() |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0042177111 | Esophagus | ESCC | negative regulation of protein catabolic process | 84/8552 | 121/18723 | 1.03e-07 | 1.69e-06 | 84 |
| GO:00421477 | Esophagus | ESCC | retrograde transport, endosome to Golgi | 63/8552 | 91/18723 | 4.58e-06 | 4.87e-05 | 63 |
| GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
| GO:1903363110 | Esophagus | ESCC | negative regulation of cellular protein catabolic process | 51/8552 | 75/18723 | 7.70e-05 | 5.74e-04 | 51 |
| GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
| GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
| GO:004308715 | Esophagus | ESCC | regulation of GTPase activity | 183/8552 | 348/18723 | 5.34e-03 | 2.00e-02 | 183 |
| GO:19048881 | Esophagus | ESCC | cranial skeletal system development | 41/8552 | 68/18723 | 1.07e-02 | 3.66e-02 | 41 |
| GO:19030532 | Esophagus | ESCC | regulation of extracellular matrix organization | 30/8552 | 48/18723 | 1.40e-02 | 4.57e-02 | 30 |
| Page: 1 2 3 4 5 |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RIC1 | SNV | Missense_Mutation | c.2884C>G | p.Leu962Val | p.L962V | Q4ADV7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| RIC1 | SNV | Missense_Mutation | c.3255N>T | p.Gln1085His | p.Q1085H | Q4ADV7 | protein_coding | tolerated(0.45) | benign(0.011) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| RIC1 | SNV | Missense_Mutation | c.2816N>T | p.Ala939Val | p.A939V | Q4ADV7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| RIC1 | SNV | Missense_Mutation | c.2822N>T | p.Ser941Phe | p.S941F | Q4ADV7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| RIC1 | SNV | Missense_Mutation | c.2875N>A | p.Ala959Thr | p.A959T | Q4ADV7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RIC1 | SNV | Missense_Mutation | novel | c.1097G>T | p.Ser366Ile | p.S366I | Q4ADV7 | protein_coding | tolerated(0.06) | benign(0.028) | TCGA-AC-A8OR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RIC1 | SNV | Missense_Mutation | c.3750G>T | p.Met1250Ile | p.M1250I | Q4ADV7 | protein_coding | tolerated(0.1) | benign(0.015) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RIC1 | SNV | Missense_Mutation | c.2140G>C | p.Ala714Pro | p.A714P | Q4ADV7 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| RIC1 | SNV | Missense_Mutation | novel | c.2399C>T | p.Ser800Phe | p.S800F | Q4ADV7 | protein_coding | deleterious(0.02) | benign(0.005) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RIC1 | SNV | Missense_Mutation | rs374147809 | c.3885N>C | p.Gln1295His | p.Q1295H | Q4ADV7 | protein_coding | deleterious(0.01) | possibly_damaging(0.862) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |